Vanguard Group Inc Intellia Therapeutics, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.97 Trillion
- Q2 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding NTLA
# of Institutions
333Shares Held
97.2MCall Options Held
1.66MPut Options Held
1.03M-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl13MShares$260 Million1.01% of portfolio
-
Black Rock Inc. New York, NY9.6MShares$192 Million0.0% of portfolio
-
Morgan Stanley New York, NY4.12MShares$82.2 Million0.0% of portfolio
-
State Street Corp Boston, MA4.04MShares$80.6 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY2.68MShares$53.4 Million0.25% of portfolio
About Intellia Therapeutics, Inc.
- Ticker NTLA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 76,011,800
- Market Cap $1.52B
- Description
- Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...